[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioage Labs Inc (BIOA)

Bioage Labs Inc (BIOA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 525,521
  • Shares Outstanding, K 45,897
  • Annual Sales, $ 9,000 K
  • Annual Income, $ -80,610 K
  • EBIT $ -106 M
  • EBITDA $ -106 M
  • 60-Month Beta 0.94
  • Price/Sales 59.80
  • Price/Cash Flow N/A
  • Price/Book 1.39

Options Overview Details

View History
  • Implied Volatility 146.19% (+40.40%)
  • Historical Volatility 300.94%
  • IV Percentile 64%
  • IV Rank 20.80%
  • IV High 511.33% on 11/19/25
  • IV Low 50.29% on 09/17/25
  • Expected Move (DTE 10) 1.15 (10.75%)
  • Put/Call Vol Ratio 46.36
  • Today's Volume 521
  • Volume Avg (30-Day) 1,285
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 18,981
  • Open Int (30-Day) 18,287
  • Expected Range 9.52 to 11.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.66
  • Number of Estimates 5
  • High Estimate $-0.42
  • Low Estimate $-0.87
  • Prior Year $-0.56
  • Growth Rate Est. (year over year) -17.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.65 +23.35%
on 07/31/26
24.91 -57.17%
on 07/30/26
-13.67 (-56.16%)
since 07/10/26
3-Month
8.65 +23.35%
on 07/31/26
25.95 -58.89%
on 07/06/26
-7.49 (-41.24%)
since 05/11/26
52-Week
4.33 +146.42%
on 08/12/25
25.95 -58.89%
on 07/06/26
+6.33 (+145.85%)
since 08/11/25

Most Recent Stories

More News
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026...

BIOA : 10.67 (-6.81%)
BioAge Labs' Longevity Data Look Promising, but the Market Still Wants Revenue

Barchart Research What to Expect from BIOA Earnings BIOA Generated August 4, 2026 Current Price $11.20 EPS Estimate $$-0.65 Consensus Rating Moderate Buy Average Move 5.38% BioAge Labs' Longevity Data...

BIOA : 10.67 (-6.81%)
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

STOCKHOLM , July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER)...

BIOA : 10.67 (-6.81%)
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk...

BIOA : 10.67 (-6.81%)
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease

BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts...

BIOA : 10.67 (-6.81%)
BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic...

BIOA : 10.67 (-6.81%)
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.1167 (+1.48%)
BIOA : 10.67 (-6.81%)
LCTX : 1.1200 (-0.88%)
GERN : 1.6300 (+10.14%)
FATE : 2.74 (-0.72%)
BioAge Labs Enters Its First Quarter Judged Entirely on Pipeline Execution

Barchart Research What to Expect from BIOA Earnings BIOA Generated May 11, 2026 Current Price $18.16 EPS Estimate $$-0.69 Consensus Rating Moderate Buy Average Move 6.27% BioAge Labs Enters Its First Quarter...

BIOA : 10.67 (-6.81%)
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular...

BIOA : 10.67 (-6.81%)
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept...

BIOA : 10.67 (-6.81%)

Business Summary

BioAge Labs Inc. is a clinical-stage biopharmaceutical company. It involved in developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging. BioAge Labs Inc. is based in RICHMOND, Calif.

See More

Key Turning Points

3rd Resistance Point 12.44
2nd Resistance Point 12.00
1st Resistance Point 11.33
Last Price 10.67
1st Support Level 10.22
2nd Support Level 9.78
3rd Support Level 9.11

See More

52-Week High 25.95
Fibonacci 61.8% 17.69
Fibonacci 50% 15.14
Fibonacci 38.2% 12.59
Last Price 10.67
52-Week Low 4.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.